 | Vol. 14.47 – 16 December, 2020 |
| |
|
|
| Using patient-derived cellular models, researchers showed that loss of ZFAND3 hampered the invasive capacity of glioblastoma, whereas ZFAND3 overexpression increased motility in cells that were initially not invasive. [Nature Communications] |
|
|
|
 | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators showed that ALS-associated Fused in Sarcoma (FUS) RNA-binding protein aberrantly contacted U1 snRNA at the Sm site with its zinc finger and trapped snRNP biogenesis intermediates in human and murine motor neurons. [Nature Communications] |
|
|
|
| Scientists showed that interactions between SATB2, a chromosomal scaffolding protein, and the inner nuclear membrane protein LEMD2, orchestrated the response of pyramidal neurons to neuronal activation. [EMBO Journal] |
|
|
|
| Glioblastoma cells that are part of the tumor microtube-connected tumor network showed activated neurodevelopmental and glioma progression gene expression pathways. Importantly, many of them revealed profiles indicative of increased cellular stemness, including high expression of nestin. [Neuro-Oncology] |
|
|
|
| The authors found that Talpid3, related to Joubert syndrome, was localized to the mother centriole of radial glial cells and was required for their apical mitosis. [Cell Reports] |
|
|
|
| Scientists investigated the roles of hypoxia–reoxygenation-induced release of high mobility group box protein 1, a risk molecule for Alzheimer’s disease pathogenesis in the ischaemic damaged brain, from human brain microvascular endothelial cells in neuronal amyloid-beta production. [Cell Death & Disease] |
|
|
|
| Due to the inaccessibility of brain tissues from human Niemann-Pick disease, type C (NPC) patients, investigators developed NPC brain organoids with induced neural stem cells from NPC patient-derived fibroblasts. [Cell Death & Disease] |
|
|
|
| Researchers demonstrated that both Wnt5a and miRNA200b-3p could promote neural stem cell (NSC) differentiation into neurons and that Wnt5a upregulated miRNA200b-3p expression through MAPK/JNK signaling to promote NSC differentiation into neurons. [Experimental and Molecular Medicine] |
|
|
|
| The authors utilized glioblastoma neurospheres that displayed glioblastoma stem cell characteristics and found activation of the PI3K/AKT pathway in sphere-forming cells. The PI3Kα selective inhibitor alpelisib blocked PI3K/AKT activation and inhibited spheroid growth, suggesting an essential role for the PI3Kα catalytic isoform. [Scientific Reports] |
|
|
|
| All of the western blot, immunocytochemical, and immunohistochemical analyses showed that mRib72-pAb crossreacted with several mouse proteins besides myoclonin1, while 6A3-mAb specifically recognized myoclonin1 and detected it only in cells with motile cilia but not in neurons. [Scientific Reports] |
|
|
|
| Scientists elucidated the role of the epigenetic regulatory network involving ubiquitously transcribed tetratricopeptide repeat on chromosome X (UTX)/miR-24/NeuroD1 in axonal regeneration and functional recovery in mice following spinal cord injury (SCI). They showed that UTX was significantly increased post-SCI and repressed axonal regeneration in vitro. [Molecular Therapy-Methods & Clinical Development] |
|
|
|
| The authors evaluated 4‐Methoxydalbergione (4MOD) anti-astroglioma effects on both in vitro and in vivo models. In cultured astroglioma U87 cells, 4MOD inhibited cell proliferation and induced cell apoptosis in a time- and concentration-dependent manner. [Acta Pharmacologica Sinica] |
|
|
|
|
| Investigators discuss the interrelationships between neuroinflammation and amyloid and tau pathologies as well as the effect of neuroinflammation on the disease trajectory in Alzheimer’s disease. They specifically focus on microglia as major players in neuroinflammation and discuss the spatial and temporal variations in microglial phenotypes that are observed under different conditions. [Nature Reviews Neurology] |
|
|
|
| The authors highlight the most significant developments that have led to microphysiological human mini-brain models. [Nature Biomedical Engineering] |
|
|
|
| Scientists describe the differences in neurotransmission and neuromodulation between newly evolved vs. primary sensory cortices and then speculate on how these disparities may underlie the susceptibility of dorsolateral prefrontal cortex circuits in mental disorders. [Molecular Psychiatry] |
|
|
|
|
| Novocure announced that the Swiss Federal Office of Public Health has added Optune® in combination with temozolomide to the List of Remedies and Equipment for the treatment of patients with newly diagnosed glioblastoma, effective April 1, 2021. [Novocure] |
|
|
|
| Genentech, Inc. announced that the FDA has approved a shorter two-hour infusion time for Ocrevus®, dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis who have not experienced any prior serious infusion reactions. [Genentech, Inc.] |
|
|
|
| Prevail Therapeutics Inc.announced that the first patient has been dosed in the Phase I/II PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations. [Prevail Therapeutics Inc.] |
|
|
|
|
| January 7 – 8, 2021 Virtual |
|
|
|
|
|
| Flanders Institute for Biotechnology – Antwerp, Belgium |
|
|
|
| University College London – London, England, United Kingdom |
|
|
|
| Lerner Research Institute, Cleveland Clinic – Cleveland, Ohio, United States |
|
|
|
| Lieber Institute for Brain Development – Baltimore, Maryland, United States |
|
|
|
| Genentech, Inc. – South San Francisco, California, United States |
|
|
|
|